Search Results for “Customizable SAP E_S4HCON2023 Practice Exam Software 🐂 Easily obtain ➠ E_S4HCON2023 🠰 for free download through ⇛ www.pdfvce.com ⇚ 🛐E_S4HCON2023 Exam Practice” – Page 29

Diagnosis of urticaria

33.	Schoepke, N., Doumoulakis, G., and Maurer, M.+: Diagnosis of urticaria. In: Godse, K., editor: Urticaria. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd., 2016

bc.33

32.	Maurer, M., Magerl, M., Zuberbier, T., and Weller, K.: Urticaria. In: Kabashima, K., editor: Immunology of the skin. Japan: Springer, 2016

58.	Weller, K., Soost, S., Worm, M., Maurer, M., and Zuberbier, T.: Atopic dermatitis and allergic rhinitis – do co-effects in therapy exist? J. Dtsch. Dermatol. Ges. 2012: 10; 221-239. IF: 1.40

364	Kulthanan, K., Chularojanamontri, L., Rujitharanawong, C., Weerasubpong, P., Maurer, M.+, and Weller, K.: Angioedema quality of life questionnaire (AE-QoL) – interpretability and sensitivity to change. Health. Qual. Life Outcomes 2019: 17; 160. IF: 2.34

o.364

30.	Maurer, M., Siebenhaar, F., Schmetzer, O., and Metz, M.: Mast cell biology and its role in the immediate skin contact reactions. In: Maibach, H. I. and Gimenez-Arnau, A., editors: Contact urticaria syndrome. 2nd ed., CRC Press, 2014

27.	Zuberbier, T. and Maurer, M.: EAACI-GA²LEN-EDF-WAO – Guideline on urticaria. In: Akdis, C. A. and Agache, I., editors: Global atlas of allergy. EAACI, 2014

Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence

129.

Maurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., and Magerl, M.: Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J. Allergy Clin. Immunol. 2018: 141; 638-649. IF: 14.11

r.129

26.	Maurer, M. and Zuberbier, T.: Hypersensitivity vasculitis. In: Akdis, C. A. and Agache, I., editors: Global atlas of allergy. EAACI, 2014

17.	Metz, M. and Maurer, M.: Mast cells – key effector cells in immune responses. Trends Immunol. 2007: 28; 234-241. IF: 9.48

Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial

Hartmann, K.+, Siebenhaar, F., Belloni, B., Brockow, K., Eben, R., Hartmann, B., Ruëff, F., Schoepke, N., Staubach, P., Weber, A., and Maurer, M.: Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized double-blind, placebo-controlled trial. Brit. J. Dermatol. 2010: 162; 185-190. IF: 4.35

o.095

Results

Search Results for: Customizable SAP E_S4HCON2023 Practice Exam Software 🐂 Easily obtain ➠ E_S4HCON2023 🠰 for free download through ⇛ www.pdfvce.com ⇚ 🛐E_S4HCON2023 Exam Practice – Page 29